CDH17 and gastric adenocarcinoma: found a strong correlation between the expression of CDH17 and the development of lymph node metastases in patients with gastric adenocarcinoma (p < 0.01, 166 patients: 40 at stage N0, 61 at stage N1, 37 at stage N2, and 28 at stage N3) [10].